Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.

MLA

Tjalma, Wiebren A. A., et al. “Subcutaneous Trastuzumab (Herceptin) versus Intravenous Trastuzumab for the Treatment of Patients with HER2-Positive Breast Cancer: A Time, Motion and Cost Assessment Study in a Lean Operating Day Care Oncology Unit.” European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 221, Feb. 2018, pp. 46–51. EBSCOhost, https://doi.org/10.1016/j.ejogrb.2017.12.006.

APA

Tjalma, W. A. A., Van den Mooter, T., Mertens, T., Bastiaens, V., Huizing, M. T., & Papadimitriou, K. (2018). Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 221, 46–51. https://doi.org/10.1016/j.ejogrb.2017.12.006

Chicago

Tjalma, Wiebren A A, Tom Van den Mooter, Tim Mertens, Valerie Bastiaens, Manon T Huizing, and Konstantinos Papadimitriou. 2018. “Subcutaneous Trastuzumab (Herceptin) versus Intravenous Trastuzumab for the Treatment of Patients with HER2-Positive Breast Cancer: A Time, Motion and Cost Assessment Study in a Lean Operating Day Care Oncology Unit.” European Journal of Obstetrics, Gynecology, and Reproductive Biology 221 (February): 46–51. doi:10.1016/j.ejogrb.2017.12.006.